Hematological Oncology considers for publication articles dealing with experimental and clinical aspects of neoplastic diseases of the hemopoietic and lymphoid systems and relevant related matters. Translational studies applying basic science to clinical issues are particularly welcomed. Manuscripts dealing with the following areas are encouraged:-Clinical practice and management of hematological neoplasia, including: acute and chronic leukemias, malignant lymphomas, myeloproliferative disorders-Diagnostic investigations, including imaging and laboratory assays-Epidemiology, pathology and pathobiology of hematological neoplasia of hematological diseases-Therapeutic issues including Phase 1, 2 or 3 trials as well as allogeneic and autologous stem cell transplantation studies-Aspects of the cell biology, molecular biology, molecular genetics and cytogenetics of normal or diseased hematopoeisis and lymphopoiesis, including stem cells and cytokines and other regulatory systems.Concise, topical review material is welcomed, especially if it makes new concepts and ideas accessible to a wider community. Proposals for review material may be discussed with the Editor-in-Chief. Collections of case material and case reports will be considered only if they have broader scientific or clinical relevance.
血液肿瘤学考虑发表文章处理实验和临床方面的肿瘤疾病的造血和淋巴系统和相关的问题。将基础科学应用于临床问题的转化研究尤其受欢迎。鼓励撰写涉及以下领域的手稿：-血液肿瘤的临床实践和管理，包括：急性和慢性白血病、恶性淋巴瘤、骨髓增生性疾病-诊断研究，包括成像和实验室分析-血液病的血液瘤形成的流行病学、病理学和病理生物学-治疗问题，包括I期、II期或III期试验以及同种异体和自体干细胞移植研究-细胞生物学、分子生物学、分子遗传学和细胞遗传学的正常或患病的造血和淋巴细胞生成，包括干细胞和细胞因子和其他调控系统。简洁，专题审查材料是受欢迎的，特别是如果它使新的概念和想法获得更广泛的社区。可与主编讨论有关审查材料的建议。仅当病例材料和病例报告具有更广泛的科学或临床相关性时，才会考虑收集这些材料和报告。
CAR T‐cell therapy: Full speed ahead
来源期刊：Hematological OncologyDOI：10.1002/hon.2591
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real‐life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart
来源期刊：Hematological OncologyDOI：10.1002/hon.2606
The modern approach to mantle cell lymphoma
来源期刊：Hematological OncologyDOI：10.1002/hon.2596
Transformed follicular lymphoma in the rituximab era: A report from the Spanish Lymphoma Oncology Group
来源期刊：Hematological OncologyDOI：10.1002/hon.2601
Characteristics and risk factors of bortezomib induced peripheral neuropathy: A systematic review of phase III trials
来源期刊：Hematological OncologyDOI：10.1002/hon.2706
Safety and tolerability of lurbinectedin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndrome
来源期刊：Hematological OncologyDOI：10.1002/hon.2557
INVESTIGATING SAFETY AND PRELIMINARY EFFICACY OF AFM13 PLUS PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA AFTER BRENTUXIMAB VEDOTIN FAILURE
来源期刊：Hematological OncologyDOI：10.1002/hon.134_2629
ZANUBRUTINIB PLUS OBINUTUZUMAB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) OR RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)
来源期刊：Hematological OncologyDOI：10.1002/hon.81_2629
RESPONSE‐ADAPTED TREATMENT WITH NIVOLUMAB AND BRENTUXIMAB VEDOTIN IN YOUNG PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA: CHECKMATE 744 SUBGROUP ANALYSES
来源期刊：Hematological OncologyDOI：10.1002/hon.26_2629
A scoring system to predict the risk of atrial fibrillation in chronic lymphocytic leukemia
来源期刊：Hematological OncologyDOI：10.1002/hon.2655
Comparison between autologous and allogeneic stem cell transplantation as salvage therapy for multiple myeloma relapsing/progressing after autologous stem cell transplantation
来源期刊：Hematological OncologyDOI：10.1002/hon.2688
THE PI3Kδ INHIBITOR ME‐401 ± RITUXIMAB IN RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), AND SMALL LYMPHOCYTIC LYMPHOMA (SLL)
来源期刊：Hematological OncologyDOI：10.1002/HON.133_2629
How to approach CLL in clinical practice
来源期刊：Hematological OncologyDOI：10.1002/hon.2583
SAKK 35/15: A PHASE I TRIAL OF OBINUTUZUMAB IN COMBINATION WITH VENETOCLAX IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA PATIENTS
来源期刊：Hematological OncologyDOI：10.1002/hon.78_2629
COPANLISIB SYNERGIES WITH CONVENTIONAL AND TARGETED AGENTS INCLUDING VENETOCLAX IN PRECLINICAL MODELS OF B‐ AND T‐CELL LYMPHOMAS
来源期刊：Hematological OncologyDOI：10.1002/hon.127_2630
Dual‐tracer PET/CT scan after injection of combined [18F]NaF and [18F]FDG outperforms MRI in the detection of myeloma lesions
来源期刊：Hematological OncologyDOI：10.1002/hon.2600
Purging with chlorambucil to prevent infusion‐related reaction before obinutuzumab administration: A monocentric pilot experience
来源期刊：Hematological OncologyDOI：10.1002/hon.2684
Extranodal lymphomas in the public health system in Chile: Analysis of 1251 patients from the National Adult Cancer Program
来源期刊：Hematological OncologyDOI：10.1002/hon.2547
Reassessment of risk factors and long‐term results of autologous stem cell transplantation in relapsed and refractory classical Hodgkin lymphoma
来源期刊：Hematological OncologyDOI：10.1002/hon.2604
Patients assigned to VGPR, PR, and SD in the IMWG response category are composed of heterogeneous population when assessed by the heavy/light chain assay
来源期刊：Hematological OncologyDOI：10.1002/hon.2611
THE ANTI‐CD25 ANTIBODY‐DRUG CONJUGATE CAMIDANLUMAB TESIRINE (ADCT‐301) PRESENTS A STRONG PRECLINICAL ACTIVITY BOTH AS SINGLE AGENT AND IN COMBINATION IN LYMPHOMA CELL LINES
来源期刊：Hematological OncologyDOI：10.1002/hon.134_2630
COST‐EFFECTIVENESS AND COST‐UTILITY ANALYSIS OF MULTIPLE TREATMENT STRATEGIES USING ABVD AND/OR BEACOPP IN THE TREATMENT OF ADVANCED‐STAGE HODGKIN LYMPHOMA
来源期刊：Hematological OncologyDOI：10.1002/hon.106_2629
INTERIM ANALYSIS OF PHASE IIIB MAGNIFY STUDY OF INDUCTION R2 FOLLOWED BY MAINTENANCE IN PATIENTS WITH RELAPSED/REFRACTORY INDOLENT NON‐HODGKIN LYMPHOMA
来源期刊：Hematological OncologyDOI：10.1002/hon.76_2629
ACCEPT: A PHASE IB/II COMBINATION OF ACALABRUTINIB WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE AND PREDNISOLONE (R‐CHOP) FOR PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL)
来源期刊：Hematological OncologyDOI：10.1002/hon.39_2629
A GENE EXPRESSION‐BASED SCORE TO PREDICT INTERIM PET POSITIVITY IN HODGKIN LYMPHOMA PATIENTS TREATED WITH ABVD
来源期刊：Hematological OncologyDOI：10.1002/hon.17_2629
THE CLINICAL COURSE OF DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) OVER TIME: A MULTISTATE SURVIVAL ANALYSIS USING META‐DATA FROM 13 FIRST‐LINE RANDOMIZED TRIALS
来源期刊：Hematological OncologyDOI：10.1002/hon.56_2630
TREATMENT AND OUTCOMES OF PATIENTS WITH NK/T‐CELL LYMPHOMA TREATED WITH MODIFIED (m)SMILE AND INTENSITY‐MODULATED RADIOTHERAPY (IMRT), A SINGLE CENTER EXPERIENCE
来源期刊：Hematological OncologyDOI：10.1002/HON.156_2631
EVITA: PHASE I/II STUDY OF EVEROLIMUS PLUS ITACITINIB IN RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA
来源期刊：Hematological OncologyDOI：10.1002/HON.22_2632
PERSONALIZED PREDICTION IN DLBCL ENABLED BY FUNCTIONAL MOUSE GENOMICS
来源期刊：Hematological OncologyDOI：10.1002/hon.8_2630
CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA FOLLOWING RETREATMENT WITH SECOND‐LINE RITUXIMAB‐CONTAINING CHEMOTHERAPY
来源期刊：Hematological OncologyDOI：10.1002/HON.67_2631
LENALIDOMIDE PLUS R‐GDP (R2‐GDP) IN RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA. PRELIMINARY RESULTS OF THE R2‐GDP‐GOTEL TRIAL
来源期刊：Hematological OncologyDOI：10.1002/HON.67_2630
PET‐CR AS A SURROGATE FOR SURVIVAL OUTCOMES IN DLBCL: A LITERATURE BASED META‐ANALYSIS
来源期刊：Hematological OncologyDOI：10.1002/hon.59_2630
POPULATION‐BASED STUDY ON DIFFERENT REGIMENS OF R‐CHOP IN PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA IN THE NETHERLANDS SUPPORTS THE USE OF 6 CYCLES OF R‐CHOP21
来源期刊：Hematological OncologyDOI：10.1002/hon.61_2630
THE PHOTOSENSITIZER VERTEPORFIN EXERTED ANTI‐TUMOR EFFECT IN DIFFUSE LARGE B‐CELL LYMPHOMA VIA DISRUPTING YAP‐TEAD COMPLEX
来源期刊：Hematological OncologyDOI：10.1002/hon.198_2631
THE IMMUNE MICROENVIRONMENT AS A PROGNOSTIC TOOL FOR MCL PATIENTS
来源期刊：Hematological OncologyDOI：10.1002/hon.6_2631
CD19/CD20‐REDIRECTED BISPECIFIC CAR T CELL TREATMENT IN PATIENTS WITH RELAPSED OR REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMA
来源期刊：Hematological OncologyDOI：10.1002/hon.116_2630
S1PR5 regulates NK cell responses in preventing graft‐versus‐host disease while preserving graft‐versus‐tumour activity in a murine allogeneic haematopoietic stem cell transplantation model
来源期刊：Hematological OncologyDOI：10.1002/hon.2669
IS IT RADIOTHERAPY NECESSARY FOR PRIMARY MEDIASTINAL B‐CELL LYMPHOMA (PMBL) PATIENTS ACHIEVING PET NEGATIVITY AFTER IMMUNOCHEMOTHERAPY?
来源期刊：Hematological OncologyDOI：10.1002/hon.77_2630
A NATIONAL RETROSPECTIVE ANALYSIS OF CLINICAL OUTCOMES FOLLOWING ALLOGENEIC TRANSPLANTATION FOR HIGH GRADE B‐CELL LYMPHOMA (HGBL)
来源期刊：Hematological OncologyDOI：10.1002/hon.116_2631
CLINICAL PRESENTATION AND MOLECULAR CHARACTERISTICS OF CUTANEOUS DLBCL
来源期刊：Hematological OncologyDOI：10.1002/hon.25_2631
THE LANDSCAPE OF DRUG PERTURBATION EFFECTS IN LEUKEMIA AND LYMPHOMA
来源期刊：Hematological OncologyDOI：10.1002/hon.87_2629
UPDATED SAFETY AND EFFICACY RESULTS OF «HLMoscow 1‐3» STUDY FOR THE 147 UNTREATED PATIENTS WITH ADVANCED CLASSICAL HODGKIN LYMPHOMA
来源期刊：Hematological OncologyDOI：10.1002/hon.169_2631
IMPACT OF PET IMAGING AND HISTOLOGIC TRANSFORMATION ON THE PROGNOSIS OF EARLY DISEASE PROGRESSION IN FOLLICULAR LYMPHOMA
来源期刊：Hematological OncologyDOI：10.1002/hon.109_2629
INCREASED CCND1 FISH SIGNALS ARE ASSOCIATED WITH WORSE PROGNOSIS IN MANTLE CELL LYMPHOMA
来源期刊：Hematological OncologyDOI：10.1002/hon.4_2631
INTRALESIONAL RITUXIMAB SUPPLEMENTED WITH AUTOLOGOUS SERUM IN RELAPSED CD20+ INDOLENT LYMPHOMAS OF THE CONJUNCTIVA: ACTIVITY AND SAFETY RESULTS OF THE “IRIS” TRIAL
来源期刊：Hematological OncologyDOI：10.1002/hon.137_2629
A PHASE II STUDY OF LENALIDOMIDE AND RITUXIMAB (R²) COMBINATION IN PATIENTS WITH HIGH‐RISK REFRACTORY/RELAPSED DIFFUSE LARGE B‐CELL LYMPHOMA
来源期刊：Hematological OncologyDOI：10.1002/HON.106_2631
A PROSPECTIVE STUDY ON THE CIRCULATION AND CENTRAL NERVOUS SYSTEM AFTERPRIMARY CENTRAL NERVOUS SYSTEM B CELL LYMPHOMATREATMENT WITH RITUXIMAB
来源期刊：Hematological OncologyDOI：10.1002/hon.139_2631
RETREATMENT WITH NIVOLUMAB IN PATIENTS WITH R/R CLASSICAL HODGKIN LYMPHOMA AFTER DISCONTINUATION OF THE THERAPY WITH IMMUNE CHECKPOINT INHIBITORS
来源期刊：Hematological OncologyDOI：10.1002/hon.176_2631
A PROSPECTIVE REGISTRY STUDY OF PEG‐G‐CSF PROPHYLAXIS FOR PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA (CISL 1403)
来源期刊：Hematological OncologyDOI：10.1002/hon.122_2631
Brentuximab vedotin and anti‐PD1 treatment optimize survival in chemo‐refractory Hodgkin lymphoma patients: Real‐world data
来源期刊：Hematological OncologyDOI：10.1002/hon.2645
